These studies, along with our own findings, suggest that ritanserin as well as other DGKα inhibitors would be good candidates to be developed clinically as anti-cancer drugs and to be used in combination with trametinib or other EGFR-Ras pathway inhibitors, particularly in Ras-driven cancers. This evidence concerns the gene EGFR and cancer.